Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors
As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological...
Gespeichert in:
| Veröffentlicht in: | ChemMedChem 2014-01, Vol.9 (1), p.217-232 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 1 |
| container_start_page | 217 |
| container_title | ChemMedChem |
| container_volume | 9 |
| creator | Defaux, Julien Antoine, Maud Le Borgne, Marc Schuster, Tilmann Seipelt, Irene Aicher, Babette Teifel, Michael Günther, Eckhard Gerlach, Matthias Marchand, Pascal |
| description | As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5‐Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1‐cyclopropyl‐3‐[7‐(1‐methyl‐1H‐pyrazol‐4‐yl)‐1,5‐naphthyridin‐4‐yl]urea (49), displayed IC50 values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer‐related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents.
Promising Aurora inhibitors: Herein we report a series of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of nanomolar‐range Aurora kinase inhibitors. The described derivatives have good cell‐penetration parameters and safety profiles, but their efficiency toward signaling pathways are insufficient to induce cell death. We also highlight their selectivity toward a panel of seven cancer‐related protein kinases. |
| doi_str_mv | 10.1002/cmdc.201300384 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01683307v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3163665701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4454-35bb0f6ce90fa987f381fc428d35a334601440006fdaf17c08f6364ddd8c08d73</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxSNERUvhyhFF4tJKeBnHju0cV1toqy4LEuXjZjmxrXXJxoudFPLf41VKhLggjTSj0e89zehl2QsMCwxQvGl2ulkUgAkAEfRRdoIFA8Sx4I_nmVfH2dMY7wAoFVg8yY4LWnCCgZ5k3y5cbPy9CWPubc7RMowt-jTUsXf90Budn-HXJdqo_bbfjsFp1yGKxvZ8CEbFPNVyCD6o_MZ1Kpr8utu62vU-xGfZkVVtNM8f-mn2-d3b29UVWn-4vF4t16ihtKSIlHUNljWmAqsqwS0R2Da0EJqUihDKAFMKAMxqZTFvQFhGGNVaizRrTk6z88l3q1q5D26nwii9cvJquZaHHWAmCAF-jxN7NrH74H8MJvZyl743bas644coMa2AkySAhL76B73zQ-jSJ4niQFhZwoFaTFQTfIzB2PkCDPKQjzzkI-d8kuDlg-1Q74ye8T-BJKCagJ-uNeN_7OTq_cXqb3M0aV3sza9Zq8J3yTjhpfy6uZS3X-DjBpiQmPwG6RKnrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1470365500</pqid></control><display><type>article</type><title>Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Defaux, Julien ; Antoine, Maud ; Le Borgne, Marc ; Schuster, Tilmann ; Seipelt, Irene ; Aicher, Babette ; Teifel, Michael ; Günther, Eckhard ; Gerlach, Matthias ; Marchand, Pascal</creator><creatorcontrib>Defaux, Julien ; Antoine, Maud ; Le Borgne, Marc ; Schuster, Tilmann ; Seipelt, Irene ; Aicher, Babette ; Teifel, Michael ; Günther, Eckhard ; Gerlach, Matthias ; Marchand, Pascal</creatorcontrib><description>As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5‐Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1‐cyclopropyl‐3‐[7‐(1‐methyl‐1H‐pyrazol‐4‐yl)‐1,5‐naphthyridin‐4‐yl]urea (49), displayed IC50 values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer‐related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents.
Promising Aurora inhibitors: Herein we report a series of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of nanomolar‐range Aurora kinase inhibitors. The described derivatives have good cell‐penetration parameters and safety profiles, but their efficiency toward signaling pathways are insufficient to induce cell death. We also highlight their selectivity toward a panel of seven cancer‐related protein kinases.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.201300384</identifier><identifier>PMID: 24273104</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>1,5‐naphthyridines ; 5-naphthyridines ; Animals ; Aurora Kinase A - antagonists & inhibitors ; Aurora Kinase A - genetics ; Aurora Kinase A - metabolism ; Aurora Kinase B - antagonists & inhibitors ; Aurora Kinase B - genetics ; Aurora Kinase B - metabolism ; aurora kinases ; Caco-2 Cells ; Cancer ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cellular Biology ; Chemical Sciences ; Drug Evaluation, Preclinical ; Half-Life ; HCT116 Cells ; heterocycles ; Humans ; inhibitors ; Kinases ; Life Sciences ; Medicinal Chemistry ; Mice ; Microsomes, Liver - metabolism ; Naphthyridines - chemistry ; Pharmaceutical sciences ; Protein Binding ; Protein Kinase Inhibitors - analogs & derivatives ; Protein Kinase Inhibitors - pharmacokinetics ; Protein Kinase Inhibitors - pharmacology ; Recombinant Proteins - biosynthesis ; Recombinant Proteins - chemistry ; Recombinant Proteins - genetics ; Structure-Activity Relationship ; Urea - analogs & derivatives ; Urea - pharmacokinetics ; Urea - pharmacology ; ureas</subject><ispartof>ChemMedChem, 2014-01, Vol.9 (1), p.217-232</ispartof><rights>Copyright © 2014 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><rights>Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4454-35bb0f6ce90fa987f381fc428d35a334601440006fdaf17c08f6364ddd8c08d73</citedby><cites>FETCH-LOGICAL-c4454-35bb0f6ce90fa987f381fc428d35a334601440006fdaf17c08f6364ddd8c08d73</cites><orcidid>0000-0003-1398-075X ; 0000-0001-7773-8642</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.201300384$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.201300384$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24273104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01683307$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Defaux, Julien</creatorcontrib><creatorcontrib>Antoine, Maud</creatorcontrib><creatorcontrib>Le Borgne, Marc</creatorcontrib><creatorcontrib>Schuster, Tilmann</creatorcontrib><creatorcontrib>Seipelt, Irene</creatorcontrib><creatorcontrib>Aicher, Babette</creatorcontrib><creatorcontrib>Teifel, Michael</creatorcontrib><creatorcontrib>Günther, Eckhard</creatorcontrib><creatorcontrib>Gerlach, Matthias</creatorcontrib><creatorcontrib>Marchand, Pascal</creatorcontrib><title>Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5‐Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1‐cyclopropyl‐3‐[7‐(1‐methyl‐1H‐pyrazol‐4‐yl)‐1,5‐naphthyridin‐4‐yl]urea (49), displayed IC50 values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer‐related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents.
Promising Aurora inhibitors: Herein we report a series of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of nanomolar‐range Aurora kinase inhibitors. The described derivatives have good cell‐penetration parameters and safety profiles, but their efficiency toward signaling pathways are insufficient to induce cell death. We also highlight their selectivity toward a panel of seven cancer‐related protein kinases.</description><subject>1,5‐naphthyridines</subject><subject>5-naphthyridines</subject><subject>Animals</subject><subject>Aurora Kinase A - antagonists & inhibitors</subject><subject>Aurora Kinase A - genetics</subject><subject>Aurora Kinase A - metabolism</subject><subject>Aurora Kinase B - antagonists & inhibitors</subject><subject>Aurora Kinase B - genetics</subject><subject>Aurora Kinase B - metabolism</subject><subject>aurora kinases</subject><subject>Caco-2 Cells</subject><subject>Cancer</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cellular Biology</subject><subject>Chemical Sciences</subject><subject>Drug Evaluation, Preclinical</subject><subject>Half-Life</subject><subject>HCT116 Cells</subject><subject>heterocycles</subject><subject>Humans</subject><subject>inhibitors</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Medicinal Chemistry</subject><subject>Mice</subject><subject>Microsomes, Liver - metabolism</subject><subject>Naphthyridines - chemistry</subject><subject>Pharmaceutical sciences</subject><subject>Protein Binding</subject><subject>Protein Kinase Inhibitors - analogs & derivatives</subject><subject>Protein Kinase Inhibitors - pharmacokinetics</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Recombinant Proteins - biosynthesis</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - genetics</subject><subject>Structure-Activity Relationship</subject><subject>Urea - analogs & derivatives</subject><subject>Urea - pharmacokinetics</subject><subject>Urea - pharmacology</subject><subject>ureas</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAQxSNERUvhyhFF4tJKeBnHju0cV1toqy4LEuXjZjmxrXXJxoudFPLf41VKhLggjTSj0e89zehl2QsMCwxQvGl2ulkUgAkAEfRRdoIFA8Sx4I_nmVfH2dMY7wAoFVg8yY4LWnCCgZ5k3y5cbPy9CWPubc7RMowt-jTUsXf90Budn-HXJdqo_bbfjsFp1yGKxvZ8CEbFPNVyCD6o_MZ1Kpr8utu62vU-xGfZkVVtNM8f-mn2-d3b29UVWn-4vF4t16ihtKSIlHUNljWmAqsqwS0R2Da0EJqUihDKAFMKAMxqZTFvQFhGGNVaizRrTk6z88l3q1q5D26nwii9cvJquZaHHWAmCAF-jxN7NrH74H8MJvZyl743bas644coMa2AkySAhL76B73zQ-jSJ4niQFhZwoFaTFQTfIzB2PkCDPKQjzzkI-d8kuDlg-1Q74ye8T-BJKCagJ-uNeN_7OTq_cXqb3M0aV3sza9Zq8J3yTjhpfy6uZS3X-DjBpiQmPwG6RKnrw</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Defaux, Julien</creator><creator>Antoine, Maud</creator><creator>Le Borgne, Marc</creator><creator>Schuster, Tilmann</creator><creator>Seipelt, Irene</creator><creator>Aicher, Babette</creator><creator>Teifel, Michael</creator><creator>Günther, Eckhard</creator><creator>Gerlach, Matthias</creator><creator>Marchand, Pascal</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><general>Wiley Subscription Services, Inc</general><general>Wiley-VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1398-075X</orcidid><orcidid>https://orcid.org/0000-0001-7773-8642</orcidid></search><sort><creationdate>201401</creationdate><title>Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors</title><author>Defaux, Julien ; Antoine, Maud ; Le Borgne, Marc ; Schuster, Tilmann ; Seipelt, Irene ; Aicher, Babette ; Teifel, Michael ; Günther, Eckhard ; Gerlach, Matthias ; Marchand, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4454-35bb0f6ce90fa987f381fc428d35a334601440006fdaf17c08f6364ddd8c08d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>1,5‐naphthyridines</topic><topic>5-naphthyridines</topic><topic>Animals</topic><topic>Aurora Kinase A - antagonists & inhibitors</topic><topic>Aurora Kinase A - genetics</topic><topic>Aurora Kinase A - metabolism</topic><topic>Aurora Kinase B - antagonists & inhibitors</topic><topic>Aurora Kinase B - genetics</topic><topic>Aurora Kinase B - metabolism</topic><topic>aurora kinases</topic><topic>Caco-2 Cells</topic><topic>Cancer</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cellular Biology</topic><topic>Chemical Sciences</topic><topic>Drug Evaluation, Preclinical</topic><topic>Half-Life</topic><topic>HCT116 Cells</topic><topic>heterocycles</topic><topic>Humans</topic><topic>inhibitors</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Medicinal Chemistry</topic><topic>Mice</topic><topic>Microsomes, Liver - metabolism</topic><topic>Naphthyridines - chemistry</topic><topic>Pharmaceutical sciences</topic><topic>Protein Binding</topic><topic>Protein Kinase Inhibitors - analogs & derivatives</topic><topic>Protein Kinase Inhibitors - pharmacokinetics</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Recombinant Proteins - biosynthesis</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - genetics</topic><topic>Structure-Activity Relationship</topic><topic>Urea - analogs & derivatives</topic><topic>Urea - pharmacokinetics</topic><topic>Urea - pharmacology</topic><topic>ureas</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Defaux, Julien</creatorcontrib><creatorcontrib>Antoine, Maud</creatorcontrib><creatorcontrib>Le Borgne, Marc</creatorcontrib><creatorcontrib>Schuster, Tilmann</creatorcontrib><creatorcontrib>Seipelt, Irene</creatorcontrib><creatorcontrib>Aicher, Babette</creatorcontrib><creatorcontrib>Teifel, Michael</creatorcontrib><creatorcontrib>Günther, Eckhard</creatorcontrib><creatorcontrib>Gerlach, Matthias</creatorcontrib><creatorcontrib>Marchand, Pascal</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Defaux, Julien</au><au>Antoine, Maud</au><au>Le Borgne, Marc</au><au>Schuster, Tilmann</au><au>Seipelt, Irene</au><au>Aicher, Babette</au><au>Teifel, Michael</au><au>Günther, Eckhard</au><au>Gerlach, Matthias</au><au>Marchand, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2014-01</date><risdate>2014</risdate><volume>9</volume><issue>1</issue><spage>217</spage><epage>232</epage><pages>217-232</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>As part of our research projects to identify new chemical entities of biological interest, we developed a synthetic approach and the biological evaluation of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of Aurora kinase inhibitors for the treatment of malignant diseases based on pathological cell proliferation. 1,5‐Naphthyridine derivatives showed excellent inhibitory activities toward Aurora kinases A and B, and the most active compound, 1‐cyclopropyl‐3‐[7‐(1‐methyl‐1H‐pyrazol‐4‐yl)‐1,5‐naphthyridin‐4‐yl]urea (49), displayed IC50 values of 13 and 107 nM against Aurora kinases A and B, respectively. In addition, the selectivity toward a panel of seven cancer‐related protein kinases was highlighted. In vitro ADME properties were also determined in order to rationalize the difficulties in correlating antiproliferative activity with Aurora kinase inhibition. Finally, the good safety profile of these compounds imparts promising potential for their further development as anticancer agents.
Promising Aurora inhibitors: Herein we report a series of (7‐aryl‐1,5‐naphthyridin‐4‐yl)ureas as a novel class of nanomolar‐range Aurora kinase inhibitors. The described derivatives have good cell‐penetration parameters and safety profiles, but their efficiency toward signaling pathways are insufficient to induce cell death. We also highlight their selectivity toward a panel of seven cancer‐related protein kinases.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>24273104</pmid><doi>10.1002/cmdc.201300384</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-1398-075X</orcidid><orcidid>https://orcid.org/0000-0001-7773-8642</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1860-7179 |
| ispartof | ChemMedChem, 2014-01, Vol.9 (1), p.217-232 |
| issn | 1860-7179 1860-7187 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01683307v1 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | 1,5‐naphthyridines 5-naphthyridines Animals Aurora Kinase A - antagonists & inhibitors Aurora Kinase A - genetics Aurora Kinase A - metabolism Aurora Kinase B - antagonists & inhibitors Aurora Kinase B - genetics Aurora Kinase B - metabolism aurora kinases Caco-2 Cells Cancer Cell Line, Tumor Cell Proliferation - drug effects Cellular Biology Chemical Sciences Drug Evaluation, Preclinical Half-Life HCT116 Cells heterocycles Humans inhibitors Kinases Life Sciences Medicinal Chemistry Mice Microsomes, Liver - metabolism Naphthyridines - chemistry Pharmaceutical sciences Protein Binding Protein Kinase Inhibitors - analogs & derivatives Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - pharmacology Recombinant Proteins - biosynthesis Recombinant Proteins - chemistry Recombinant Proteins - genetics Structure-Activity Relationship Urea - analogs & derivatives Urea - pharmacokinetics Urea - pharmacology ureas |
| title | Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A51%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%207-Aryl-Substituted%20(1,5-Naphthyridin-4-yl)ureas%20as%20Aurora%20Kinase%20Inhibitors&rft.jtitle=ChemMedChem&rft.au=Defaux,%20Julien&rft.date=2014-01&rft.volume=9&rft.issue=1&rft.spage=217&rft.epage=232&rft.pages=217-232&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.201300384&rft_dat=%3Cproquest_hal_p%3E3163665701%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1470365500&rft_id=info:pmid/24273104&rfr_iscdi=true |